The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
|
|---|---|
| Published in |
Frontiers in oncology, March 2019
|
| DOI | 10.3389/fonc.2019.00132 |
| Pubmed ID | |
| Authors |
Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Shirish M. Gadgeel, Mihaela C. Cristea, Chandra P. Belani, Edward M. Newman, David R. Gandara, Primo N. Lara |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 8% |
| Spain | 1 | 8% |
| Unknown | 11 | 85% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 46% |
| Practitioners (doctors, other healthcare professionals) | 3 | 23% |
| Science communicators (journalists, bloggers, editors) | 2 | 15% |
| Scientists | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 14% |
| Researcher | 4 | 11% |
| Student > Ph. D. Student | 4 | 11% |
| Other | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 14 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 17% |
| Biochemistry, Genetics and Molecular Biology | 5 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Chemistry | 3 | 9% |
| Mathematics | 1 | 3% |
| Other | 6 | 17% |
| Unknown | 11 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2020.
All research outputs
#4,813,403
of 25,394,764 outputs
Outputs from Frontiers in oncology
#1,680
of 22,440 outputs
Outputs of similar age
#96,065
of 365,063 outputs
Outputs of similar age from Frontiers in oncology
#41
of 259 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,440 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,063 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 259 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.